Clinical

Videos

Phillip Kuo, MD, PhD, discusses the abstract, “[68Ga]Ga-PSMA-11 PET baseline imaging as a prognostic tool for clinical outcomes to [177Lu]Lu-PSMA-617 in patients with mCRPC: A VISION substudy,” which was presented at the 2022 ASCO Annual Meeting. 

Dr. Kuo on PSMA-PET imaging biomarker research

Articles

Cleveland clinic physicians Rahul Tendulkar, MD, and Steve Huang, MD, provide expert insight on PSMA-PET imaging and explain how it has changed clinical management of patients with prostate cancer. 

How PSMA-PET scans are changing clinical practice

“These findings from the SPOTLIGHT study showed high inter-reader and intra-reader agreement for interpretation of 18F-rhPSMA-7.3 PET/CT scans in the setting of biochemical recurrence,” said Phillip Kuo, MD, PhD. 

Reader reproducibility high with 18F-rhPSMA-7.3 image interpretation in prostate cancer

"The SPOTLIGHT study [of 18F-rhPSMA-7.3] highlights what I believe is a paradigm shift with its multidisciplinary [collaboration] in prostate cancer," said Mark Fleming, MD. 

18F-rhPSMA-7.3 continues to impress in prostate cancer treatment paradigm

The target of the the PET-imaging agent 64Cu SAR-Bombesin is the Gastrin Releasing Peptide receptor (GRPr), which is found on prostate tumors as well as several other tumors

FDA authorizes trial of imaging agent for PSMA-negative prostate cancer patients

The guidelines now include the use of piflufolastat F 18, along with all approved PSMA-PET imaging agents, for the selection of prostate cancer patients to receive PSMA-targeted radioligand therapy.

NCCN, SNMMI add piflufolastat F18 to guidelines for prostate cancer imaging

177Lu-PSMA-617 is FDA-approved for the treatment of patients with PSMA-positive metastatic castration-resistant prostate cancer. 

177Lu-PSMA-617 production, trial enrollment temporarily suspended

The phase 2 STARLITE 2 trial is exploring the combination of the novel radiopharmaceutical TLX250 (177Lu-DOTA-girentuximab) and nivolumab in patients with advanced renal cell carcinoma.

Study launches of novel radiopharmaceutical TLX250 in kidney cancer

The ongoing phase 1/2 COBRA trial is exploring the PSMA-PET imaging agent 64Cu SAR-bisPSMA in patients with biochemical recurrence of prostate cancer following definitive therapy.

Treatment begins in trial of 64Cu SAR-bisPSMA in biochemically recurrent prostate cancer

“Overall, there's no known advantage or disadvantage in a head-to-head trial of either one of these, but I do think they're complementary,” says Scott T. Tagawa, MD, when discussing radium-223 dichloride and lutetium Lu 177 vipivotide tetraxetan. 

Next-Generation Imaging